TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Depression Severity Changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Masimo O3 value validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodal recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Response rate of initial treatment with SCH 727965
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate in subjects treated with SCH 727965 after disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate from pre-frail to frail status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach full enteral feedings sustained for 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of FDX104
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Ventilator Associated Pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Global dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute renal injury after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of abnormal joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Curve of Drug Concentration versus Time (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (C[max])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Peak Plasma Concentration (t[max])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Sickle Cell Trait Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in Microvascular Health Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nutritional intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in resting metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent performing physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of the investigational drug
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Severe Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum α-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in analysis of fatty acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical Performance (operative time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With Withdrawal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of MICRONEUTRALISING antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of management strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ex Vivo Total Cholesterol Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With a Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Converting From PR to CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of all cause reported gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of all cause gastroenteritis related hospital discharges
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of all cause gastroenteritis related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Change in Postoperative Facial Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Capsule Placement Into the Duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of Life (MOS-HIV)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hyperspectral fluorescence of vocal folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of onset of labor analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate drug exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest Reliability of SAFE-TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance Rate of Current VA Screening Instruments and the SAFE-TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of the SAFE-TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Entrectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Entrectinib Active Metabolite M5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Entrectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Entrectinib Active Metabolite M5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asynchronies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paCO2 at 72 h After Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Upper extremity functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain intensity change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of methadone addiction/misuse or withdrawal syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major/minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of arterial/venous thrombosis/thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of using SweetSpot
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of using SweetSpot
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete Response Rate at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in the Daily Average Number of Episodes of Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative frequency of ventilator-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Upper-extremity functional capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-discharge program enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall diagnostic yield of cryobiopsy specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antiretroviral medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Prevalence of Body contouring surgeries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of tube feeding intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recurrence of uterine contraction within 48 hours after stopping tocolytic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Completers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient satisfaction with sedation and comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicities related to radiolabelled antibody
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial Function Measured by Brachial Artery Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Nociceptin/Orphanin FQ Peptide (NOP) Receptor Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until PCA Discontinued After the Operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safe dose recommended (SDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial measures of Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serial measures of apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anti-leukaemia/myeloma effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change on the Wrinkle Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients With a Score of 21 or Greater by VAWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With FMT Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline of serum BDNF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal Peak Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Development During the Preparation Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Development During the Acceleration Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory changes in endobronchial biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height standard deviation score for chronological age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood perfusion units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with at least one Treatment Emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hannover Functional Ability Questionnaire (HFAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain Score in Legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expiratory flow limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of change in expiratory flow limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in actinic keratoses and photoaged skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Axial Elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of TL1A in psoriatic skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent diffusion coefficient (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rates of molecular markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvessel density (MVD) and microlymphatic density (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vestibular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood CD3+ CD4+ counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Complete the Recommended Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in total Nail Psoriasis Severity Index (NAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Headache Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of transplant
Endpoint domain: Mortality/survival
Primary endpoint: Total time of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Adverse Reaction (Leucopenia)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability ratings
Endpoint domain: Adverse events/effects
Primary endpoint: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment engagement/retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of subjects with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hepassocin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response rate at 48 weeks of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waistline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of a Positive Cancer Biopsy
Endpoint domain: Mortality/survival
Primary endpoint: postoperative narcotic drug need
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HIV Transmission Risk
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological emotional response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrodermal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Changes From Baseline in Triglycerides (TG) to Cholesterol Ratio in sdLDL Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Mean Particle Sizes of Small Dense Low Density Lipoprotein-cholesterol (sdLDL-C) and Low Density Lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bilateral quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in quadriceps muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complications of robotic assisted surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Hemostatic Efficacy Assessment 24 Hours Post Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Factor VIII (FVIII) Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rates (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of healing with Linezolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of healing with Vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Drilling accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-age z-score (WAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best Overall Response Rate (ORR) of Subjects With BM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Overall Response Rate (ORR) of Subjects With LM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of the programs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 10 meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee angle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ankle angle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-vaccination Geometric Mean Titer (GMT) Ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention adherence and retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of First Case of Malaria
Endpoint domain: Adverse events/effects
Primary endpoint: PWV Equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse Rate Equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body Weight Equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent writing reports
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early extubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Compliant With Follow-up Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Headache Impact Test
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Breast aesthetic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast measures in centimeters and degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrepancy between objective and subjective cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood test for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood test for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS (Visual Analog Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Elimination half-life (t1/2) of 3BNC117-LS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (CL/F) of 3BNC117-LS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes